Biogen is a company which develops, markets and manufactures therapies for people with rare diseases, including hemophilia.
In 2016, Biogen started it plan to spin off its hemophilia drug business, making it a publicly traded company. In 2017, Biogen announced that it had completed the separation of its global hemophilia business.
Bioverativ, the new company, focuses on the treatments of hemophilia and other blood disorders. It provides major advanced treatments therapies treatment of hemophilia A and B.
Keywords: biogen hemophilia